This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Monitoring recommendations

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Monitor:

  • FBC every two weeks for the first six months; then every two months
  • LFTs and blood pressure - measured monthl for the first six months and then every two months

Stop drug, inform specialist if:

  • WBC < 3.5 x 10^9/l, or,
  • platelets < 150 x 10^9/l, or,
  • if ALT > twice upper limit of normal on two occasions

Note in cases of severe haematological reactions, leflunomide and concomitant myelosuppressives must be discontinued; also a leflunomide wash-out procedure must be initiated.

Reference:

  1. Doctor magazine (December 2002). Disease-modifying anti-rheumatic drugs.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.